Addex Therapeutics (ADXN) Income from Continuing Operations (2018 - 2025)

Addex Therapeutics has disclosed Income from Continuing Operations across 8 years of filings, most recently posting 2294122.41 for Q4 2025.

• Income from Continuing Operations for Q4 2025 came in at 2294122.41, down 68.91% year-over-year; the trailing twelve-month figure through Dec 2025 was 8270177.21 (down 48.36% YoY), and the FY2025 annual result was 8253040.36, down 47.27% from the prior year.
• Income from Continuing Operations came in at 2294122.41 for Q4 2025 at Addex Therapeutics, down from 1971711.48 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 6590049.23 in Q4 2022 to a low of 7497775.44 in Q2 2022.
• The 5-year median for Income from Continuing Operations is 1867423.07 (2024), against an average of 2244416.71.
• Across the five-year window, Income from Continuing Operations surged 237.36% in 2022 and sank 177.79% in 2024, its largest moves.
• Addex Therapeutics' Income from Continuing Operations stood at 4797792.82 in 2021, then soared by 237.36% to 6590049.23 in 2022, then slumped by 115.36% to 1012377.85 in 2023, then sank by 34.16% to 1358218.08 in 2024, then plunged by 68.91% to 2294122.41 in 2025.
• The last three Income from Continuing Operations figures came in at 2294122.41 (Q4 2025), 1971711.48 (Q3 2025), and 2366150.66 (Q2 2025), per Business Quant data.